Sublingual immunotherapy with monomeric carbamylated allergoid (LAIS) is an effective and well tolerated treatment of respiratory allergy. The aim of the present study was to correlate the efficacy of two maintenance doses (1000 AU vs 3000 AU) of LAIS with the immunological modulation of allergen-driven Th1, Th2 and T regulatory cytokines produced in vitro by PBMCs, in patients suffering from mite allergic rhinitis. The efficacy of LAIS is correlated to the immune modulation in a clear dose-dependent effect.
Dose-dependent clinical and immunological efficacy of sublingual immunotherapy with mite monomeric allergoid
DI GIOACCHINO, Mario;BALLONE, Enzo;TURI, MARIA COSTANZA;PETRARCA, CLAUDIA
2012-01-01
Abstract
Sublingual immunotherapy with monomeric carbamylated allergoid (LAIS) is an effective and well tolerated treatment of respiratory allergy. The aim of the present study was to correlate the efficacy of two maintenance doses (1000 AU vs 3000 AU) of LAIS with the immunological modulation of allergen-driven Th1, Th2 and T regulatory cytokines produced in vitro by PBMCs, in patients suffering from mite allergic rhinitis. The efficacy of LAIS is correlated to the immune modulation in a clear dose-dependent effect.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Dose dependent clinical immunological efficacy sublingual immunoterapy_PETRARCA.pdf
Solo gestori archivio
Tipologia:
PDF editoriale
Dimensione
1.89 MB
Formato
Adobe PDF
|
1.89 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
